Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to create an appearance of revenue, and inadequate internal controls. Investors who purchased ADMA Biologics securities during the class period may be entitled to compensation through a contingency fee arrangement. To serve as lead plaintiff, investors must move the Court no later than August 10, 2026.
ADMA Biologics IncSecurities class action lawsuit alleges false statements, undisclosed related party transaction, channel stuffing, and inadequate internal controls.